^
Association details:
| Biomarker: | MTOR F2108L |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | RapaLink-1 (mTOR inhibitor, mTORC1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Overcoming mTOR Resistance Mutations with a New Generation mTOR Inhibitor
Excerpt:
RapaLink-1 at low doses (3–10 nM) was the only drug regimen capable of inhibiting mTOR signaling in both F2108L mTOR and M2327I mTOR expressing cells (Figures 4a, b).
DOI:
10.1038/nature17963
